• B D Henderson, N Isaac, O Mabele, S Khiba, A Nkayi, and T Mokoena.
• Division of Clinical Genetics, University of the Free State, and Universitas Hospital, Bloemfontein, South Africa. gnmgbdh@ufs.ac.za.
• S. Afr. Med. J. 2016 May 25; 106 (6 Suppl 1): S47-9.

BackgroundOsteogenesis imperfecta is a heritable disorder of bone connective tissue. Type III has a high incidence in the black pop-ulation of South Africa. Affected people experience numerous fractures, bone pain and progressive disability. Until the introduction of bisphosphonates to reduce fracture incidence, treatment revolved around orthopaedic and supportive care. Objective. To assess the subjective attitude of patients towards pamidronate treatment.MethodsThirty black patients with osteogenesis imperfecta type III treated at Universitas Hospital were approached and 26 were included in this study. Patients or their parents were interviewed using a standardised researcher-administered questionnaire, either in person or by telephone.ResultsMost patients reported a reduction in symptoms, a feeling of increased wellbeing, increased strength and rated the pamidronate treatment highly. The intravenous route of administration and the side-effects experienced were bearable. Overall all patients would recommend this treatment to other affected persons.ConclusionThis is first study to look at bisphosphonate treatment for osteogenesis imperfecta type III in black South Africans. The treatment is well tolerated and highly rated by the patients. Reported improvements and side-effects are similar to those reported in other populations. Using this form of treatment in this population is supported by these findings.

24 keywords...

hide…